ALDACTONE (Spironolactone Tablets, USP) Overdosage

Medical Information
Canada
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for Canadian Healthcare Professionals. Would you like to proceed?

Symptoms:  There have been no reports of fatal overdose in man (except indirectly through hyperkalemia).  Nausea and vomiting occurs, and (much more rarely) drowsiness, dizziness, mental confusion, diarrhea, or a maculopapular or erythematous rash.  These manifestations disappear promptly on discontinuation of medication.  Hyperkalemia may be exacerbated.

Treatment:  No specific antidote.  No persistent toxicity has occurred or is expected.  Inducing vomiting and evacuating the stomach by lavage could be considered. Spironolactone use should be discontinued and potassium intake (including dietary sources) restricted.

For management of a suspected drug overdose, contact your regional Poison Control Centre.